share_log

What's Going On With Hims & Hers Health Stock Tuesday?

What's Going On With Hims & Hers Health Stock Tuesday?

Hims和Hers健康股票週二發生了什麼?
Benzinga ·  00:01

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading higher Tuesday after the company reported strong third-quarter results and raised its full-year revenue outlook. Here's what you need to know.

Hims & Hers Hers Health Inc.(紐約證券交易所代碼:HIMS)週二股價走高,此前該公司公佈了強勁的第三季度業績並上調了全年收入展望。以下是你需要知道的。

What To Know: Hims & Hers Health reported third-quarter earnings per share of 32 cents, beating estimates of 4 cents. Revenue for the quarter reached $401.6 million, surpassing expectations of $382.2 million and marking a substantial rise from $226.7 million in the same period last year.

須知:Hims & Hers Health公佈的第三季度每股收益爲32美分,超過預期的4美分。該季度的收入達到4.016億美元,超過了預期的3.822億美元,較去年同期的2.267億美元大幅增長。

The company said its subscriber base has grown to 2 million, representing a 44% increase year-over-year. Gross margin for the third quarter was 79%. Hims & Hers also reported net income of $75.6 million, representing a significant turnaround from the $7.6 million net loss reported in third quarter of 2023.

該公司表示,其用戶群已增長到200萬,同比增長44%。第三季度的毛利率爲79%。Hims & Hers還公佈了7,560萬美元的淨收入,與2023年第三季度公佈的760萬美元淨虧損相比有了重大轉機。

"In the third quarter, we eclipsed 2 million subscribers on our platform, with more than 1 million utilizing a personalized solution. These are significant milestones and confirm we are on a path to helping an American in every household feel great through the power of better health," said Andrew Dudum, co-founder and CEO of Hims & Hers Health.

「在第三季度,我們在平台上的訂閱人數超過了200萬,其中超過100萬人使用了個性化解決方案。這些都是重要的里程碑,證實我們正在通過改善健康的力量幫助每個家庭的美國人感覺良好。」 Hims & Hers Health聯合創始人兼首席執行官安德魯·杜杜姆說。

Hims & Hers raised its fiscal 2024 revenue guidance to $1.46 billion to $1.465 billion, versus estimates of $1.396 billion. The company said it expects fourth-quarter revenue to range between $465 million and $470 million.

Hims & Hers將其2024財年的收入預期上調至14.6億美元至14.65億美元,而估計爲13.96億美元。該公司表示,預計第四季度收入將在4.65億美元至4.7億美元之間。

Following the print, Canaccord Genuity analyst Maria Ripps maintained Hims & Hers Health with a Buy rating and raised the price target from $24 to $28.

印發後,Canaccord Genuity分析師瑪麗亞·裏普斯以買入評級維持Hims & Hers Hers的健康,並將目標股價從24美元上調至28美元。

Hims Price Action: Hims & Hers shares were up 5.39% at $21.89 at the time of writing, according to Benzinga Pro.

他的價格走勢:根據Benzinga Pro的數據,在撰寫本文時,Hims & Hers的股價上漲了5.39%,至21.89美元。

  • '30% Less Than Blue': Swing State Home Prices Align With Red States, Says Realtor.com
  • 「比藍州低30%」:Realtor.com表示,搖擺州房價與紅州一致

Image: Mohamed Hassan from Pixabay.

圖片:來自 Pixabay 的穆罕默德·哈桑。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論